Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Nat Commun. 2021 Feb 24;12(1):1261. doi: 10.1038/s41467-021-21396-w.
Nat Commun. 2021.
PMID: 33627640
Free PMC article.